| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10583205 | POLAREAN | Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices |
Feb, 2035
(11 years from now) | |
| US11052161 | POLAREAN | Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices |
Dec, 2035
(12 years from now) | |
Xenoview is owned by Polarean.
Xenoview contains Xenon Xe-129 Hyperpolarized.
Xenoview has a total of 2 drug patents out of which 0 drug patents have expired.
Xenoview was authorised for market use on 23 December, 2022.
Xenoview is available in gas;inhalation dosage forms.
Drug patent challenges can be filed against Xenoview from 2026-12-23.
The generics of Xenoview are possible to be released after 29 December, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 23, 2027 |
Drugs and Companies using XENON XE-129 HYPERPOLARIZED ingredient
NCE-1 date: 2026-12-23
Market Authorisation Date: 23 December, 2022
Treatment: NA
Dosage: GAS;INHALATION
XENOVIEW family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic